Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia
Susan O’Brien
SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology meeting in Atlanta. Sarah Maxwell reports.
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology meeting in Atlanta. Sarah Maxwell reports.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/071209_susan_o_brien.mp3]
